Health Condition 1: L80- Vitiligo
Conditions
Interventions
Intervention1: 2% tofacitinib ointment: 2% tofacitinib ointment local application twice daily for 16 weeks
Control Intervention1: 0.1% tacrolimus ointment: 0.1% tacrolimus ointment local application t
Sponsors
Dr Vibhu Mendiratta
Eligibility
Inclusion criteria
Inclusion criteria: Patients with active localized vitiligo. Body surface area of lesions less than 10 precent
Exclusion criteria
Exclusion criteria: acrofacial, mucosal, genital, vitiligo universalis. History of any topical or systemic medication in last three months. Child with rapidly progressing vitiligo which requires systemic treatment within 12 weeks of initiating topical therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean area repigmentation in group A tofacitinib ointment and group B tacrolimus ointment at 16 weeks from baseline.Timepoint: Mean area repigmentation in group A tofacitinib ointment and group B tacrolimus ointment at 16 weeks from baseline. | — |
Secondary
| Measure | Time frame |
|---|---|
| proportion of patients experiencing cutaneous side effects in both groupsTimepoint: baseline, 4 weeks, 8 weeks, 12 weeks & 16 weeks;proportions of patients having systemic comorbiditiesTimepoint: baseline;proportion of patients in each group , aged between 10-18 years, having improvement in quality of life, according to CDLQITimepoint: baseline & 16 weeks | — |
Countries
India
Contacts
Public ContactKUSHAL BRAR
lady hardinge medical college, delhi, india
Outcome results
None listed